|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
From a cohort of 1000 men treated for PCa by radical prostatectomy, FA composition of PPAT was analysed in 156 patients (106 Caucasians and 50 African-Caribbeans), 78 with an indolent tumour (ISUP group 1 + pT2 + PSA <10 ng/mL) and 78 with an aggressive tumour (ISUP group 4-5 + pT3).
|
29413967 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer.
|
30592769 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Albumin was positively associated with Gleason 4 + 3 tumour (1.38; 1.02-1.86) and overall death (HR<sub>unit increase in log</sub> : 1.60; 95% CI: 1.11-2.30), but inversely associated with high risk PCa and high PSA levels (≥20 µg/L) (0.71; 0.56-0.89 and 0.72; 0.5 9-0.90).
|
29322512 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA is enzymatically active in the tumor microenvironment but is presumed to be enzymatically inactive in the blood due to complex formation with serum protease inhibitors α-1-antichymotrypsin and α-2-macroglobulin (A2M).
|
29659051 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The grouping was applied according to the clinical routine laboratory parameters (vitamin D<sub>3</sub>) and the tumor markers (PSA, fPFA).
|
29886377 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When D'Amico intermediate-risk patients are evaluated, for T3 patients PSA and PNB tumor percentage; for PNI positive patients PNB core number and tumor percentage; and for BR positive patients PNB PNI positivity were significantly higher compared to T2, PNI negative and BR negative patients, separately (p < 0.05).
|
30063011 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tissue kallikrein, the oldest member and kinin-releasing enzyme, and KLK3/PSA, a tumor biomarker for prostate cancer are the most prominent components of the family.
|
29885274 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The PSA level correlated significantly with total uptake of MIP-1404 in tumors (P < 0.001).
|
29105797 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Various secondary endpoints are assessed: variations of different biomarkers at the tumour level (tissue microarrays to evaluate DNA-PKs, PARP, AR and splice variants, PSMA, etc.), whole transcriptome sequencing, exome sequencing and clinical (PSA and testosterone kinetics, early biochemical recurrence free survival, quality of life, safety, etc.) and radiological endpoints.
|
29606109 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PSA and miR-155 gene expression in tumor tissue were detected by using Real-time PCR.
|
29630104 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with MP had worse tumor characteristics such as higher Gleason Scores (GS), rapid PSA doubling-time (DT), and shorter RP-BCR time intervals.
|
29570821 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PSCA expression was associated with favorable pathological and clinical tumor features: Early pathological tumor stage (p < 0.0001), low Gleason grade (p < 0.0001), absence of lymph node metastasis (p < 0.0001), low pre-operative PSA level (p = 0.0118), negative surgical margin (p < 0.0001) and reduced PSA recurrence (p < 0.0001).
|
29855276 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA-densities were 433.9 ng/mL per milliliter tumor for VCaP-, 6.5 ng/mL per milliliter tumor for LuCaP136-, and 11.2 ng/mL per milliliter tumor for LuCaP147-xenografts.
|
29572953 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mRNA expression of RANK was highest in tumour tissue from patients with bone metastases (p < 0.001) as compared to BPH or locally confined tumours, also shown in clinical subgroups distinguished by Gleason Score (< 7 or ≥ 7, p = 0.028) or PSA level (< 10 or ≥ 10 µg/l, p = 0.004).
|
29204705 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Inter-racial difference in SUVmax of the primary tumor as well as its correlation with serum PSA were also determined.
|
29101444 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Obesity suppresses tumor attributable PSA, affecting risk categorization.
|
29661963 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The 16p13.3 gain was detected in 42% (113/267) of the specimens scorable by FISH and was significantly associated with clinicopathologic features of aggressive prostate cancer, including high preoperative PSA (<i>P</i> = 0.03) levels, high Gleason score (GS, <i>P</i> < 0.0001), advanced pathologic tumor stage (<i>P</i> < 0.0001), and positive surgical margins (<i>P</i> = 0.009).
|
28993510 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> To investigate whether prebiopsy multi-parametric (mp) MRI can help to improve predictive performance in prostate cancer.<b>Experimental Design:</b> Based on a support vector machine (SVM) analysis, we prospectively modeled clinical data (age, PSA, digital rectal examination, transrectal ultrasound, PSA density, and prostate volume) and mp-MRI findings [Prostate Imaging and Reporting and Data System (PI-RADS) score and tumor-node-metastasis stage] in 985 men to predict the risk of prostate cancer.
|
28143868 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA marker monitoring is more reliable than ultrasound or fluorescence imaging for the detection of the presence of tumors in the bladder.
|
28117816 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the leiomyomas with 12q rearrangements, both HMGA2 and PLAG1 were expressed whereas in the tumors with 8q aberrations, only PLAG1 was expressed.
|
28591699 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum PSA and tumor volumes were higher in men with undetectable versus detectable tissue abiraterone at prostatectomy (median 0.10 vs. 0.03 ng/dL, <i>P</i> = 0.02; 1.28 vs. 0.44 cc, <i>P</i> = 0.09, respectively).
|
28389510 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preliminary experiments revealed that the PSA-BS18 was a potential material for targeting tumor site with superior curative effects.
|
28678638 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clinical indicators of aggressive prostate cancer behaviour such as PSA levels, PSA doubling time or the Gleason score of the primary tumour, as well as the androgen deprivation therapy, radiation therapy or chemotherapy status are not related to measured tracer uptake.
|
29044297 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study to examine whether the serum LacdiNAc carrying prostate-specific antigen-glycosylation isomer (PSA-Gi) and WFA-reactivity of tumor tissue can be applied as a diagnostic and prognostic marker of prostate cancer (PCa).
|
28134773 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>68</sup>Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
|
28138747 |
2017 |